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Abstract
 
Aims
 
High-density lipoprotein (HDL) protects against atherosclerosis development. Defective functioning of HDL in
Type 2 diabetes may be one cause of increased cardiovascular disease associated with Type 2 diabetes. HDL modulates
low-density lipoprotein and cell membrane oxidation through the action of paraoxonase-1 (PON1), which is one of the
major mechanisms by which HDL is anti-atherogenic.
 
Methods
 
We have compared the ability of HDL from Type 2 diabetic patients without coronary heart disease (CHD)
(
 
n
 
 
 
=
 
 36) to metabolize membrane lipid hydroperoxides with HDL from healthy control subjects (
 
n
 
 
 
=
 
 19) and people with
CHD but no diabetes (
 
n
 
 
 
=
 
 37).
 
Results
 
HDL from subjects with Type 2 diabetes and CHD metabolized 20% less membrane hydroperoxides than HDL
from control subjects (
 
P
 
 
 
<
 
 0.05). The PON1-192RR was least efficient in all the study groups. PON1 was glycated 
 
in vivo
 
:
(7.5% control, 12% CHD, 17% Type 2 diabetes 
 
P
 
 
 
<
 
 0.01) with QQ isoforms most glycated. 
 
In vitro
 
 glycation of PON1
reduced its ability to metabolize membrane hydroperoxides by 50% (
 
P
 
 
 
<
 
 0.001); however, glyoxidation reduced it by
80% (
 
P
 
 
 
<
 
 0.001). In the control group only there was a significant negative correlation between PON1 activity and the
ability of HDL to metabolize membrane hydroperoxides (
 
r
 
 
 
=
 
 
 
−
 
0.911, 
 
P
 
 
 
<
 
 0.001).
 
Conclusions
 
HDL from Type 2 diabetic patients without CHD has decreased ability to metabolize membrane lipid
hydroperoxides, which could lead to increased susceptibility to cardiovascular disease.
Diabet. Med. 25, 1049–1055 (2008)
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Introduction
 
The oxidation of low-density lipoprotein (LDL) in the arterial
wall is believed to be the primary event leading to the initiation
and progression of atherosclerosis [1,2]. High-density lipoprotein
(HDL), however, is protective against the development of
atherosclerosis [3,4]. The primary protective effect of HDL is
believed to be its pivotal role in reverse-cholesterol transport;
however, HDL also has anti-oxidative, anti-inflammatory and
anti-thrombotic properties [5].
HDL-associated paraoxonase-1 (PON1) is primarily respon-
sible for the anti-oxidative properties of HDL in retarding the
oxidation of LDL and cell membranes [6–10]. By modulating
the oxidation of LDL, PON1 abolishes the oxidized LDL
stimulated induction of monocyte-chemotactic protein-1
(MCP-1) production by endothelial cells, thereby preventing
monocyte/endothelial cell interaction in one of the earliest
processes of atherosclerosis [11,12]. PON1 is low in subjects
with Type 1 or Type 2 diabetes [13–15], leading to dysfunctional
HDL with impaired antioxidant capacity [15]. In Type 2
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diabetes there is an inverse relationship between PON1
activity and circulating oxidized LDL levels [16,17], indicative
of the major role of PON1 in retarding LDL oxidation. We
have recently shown that adenovirus mediated overexpression
of human PON1 in a mouse model of metabolic syndrome
significantly inhibits atherosclerosis development by reducing
ox-LDL both in plasma and the artery wall [18].
Type 2 diabetes is associated with a 3- to 4-fold increased
susceptibility in coronary heart disease (CHD) compared with
people without diabetes and HDL cholesterol is lower than in
non-diabetic subjects [19]. Increased glycation of HDL leads
to the impairment of its anti-atherosclerotic properties
[20]. 
 
In vitro 
 
glycation of HDL appears to partially inhibit
PON1 [21]. We have previously shown that HDL from people
with Type 2 diabetes but no coronary disease and HDL from
people with coronary disease but no diabetes were defective in
their capacity to metabolize oxidized-palmitoyl, arachidonyl
phosphatidylcholine (ox-PAPC) (a primary pro-inflammatory
product of LDL oxidation and PON1 substrate) compared with
HDL from control subjects [22]. Previous studies indicated that
HDL from people with Type 1 diabetes was significantly less
efficient at metabolizing erythrocyte membrane hydroperoxides
than HDL from normal control subjects [10]. It is therefore
conceivable that HDL from Type 2 diabetic subjects will be
defective in metabolizing cell membrane oxidized lipids and
that this could contribute to increased atherosclerosis in Type 2
diabetes.
Previously, using these same populations, we showed that
HDL from people with Type 2 diabetes or with CHD was
significantly less able to metabolize ox-PAPC than HDL
from control subjects [22], but we did not investigate the
mechanism(s) responsible. In the present study, we show that
this is also the case with the metabolism of cell membrane
hydroperoxides. We also report that the likely mechanism
behind this effect is the increased glycation of PON1 in people
with Type 2 diabetes and those with CHD, which inhibits
its activity.
 
Patients and methods
 
Study subjects
 
The study populations comprised 19 healthy control subjects
attending for a routine health check matched for age (
 
±
 
 5 years)
and gender with the patient groups. Thirty-six subjects with
Type 2 diabetes were recruited from Manchester Royal Infirmary.
Diabetes mellitus was diagnosed by World Health Organiza-
tion (WHO) criteria [23]. All patients were receiving statin
treatment, four were receiving calcium channel blockers, two
angiotensin-converting enzyme (ACE) inhibitors, 20 metformin
and two insulin, and none had CHD. Sixteen individuals
were free of diabetic complications and 20 had one or more
complication (16 with peripheral neuropathy, 10 with nephro-
pathy and 11 with retinopathy). The third study group comprised
37 patients with angiographically assessed CHD and no diabetes,
with 
 
>
 
 70% stenosis of at least one coronary artery. All patients
were receiving statins, seven were receivinh calcium channel
blockers and five an ACE inhibitor. The Central Manchester
Local Research Ethics Committee approved the study and all
participants gave informed consent.
Venous blood was obtained after an overnight fast. Serum
and EDTA plasma were obtained by low-speed centrifugation.
Plasma and serum were stored at 
 
−
 
20
 
°
 
C until analysis or
used immediately to prepare HDL. DNA was extracted from
lymphocytes.
 
Biochemical analysis
 
Serum total cholesterol, triglycerides, HDL cholesterol,
apolipoprotein A1 (apoA1) and B (apoB) were determined using a
Cobas Bios  II autoanalyser, using reagents and standards
provided by the manufacturer (ABX Diagnostics, Shefford,
UK). Glycated haemoglobin (HbA
 
1c
 
) was determined by HPLC
using the Variant analyser (Bio-Rad Ltd, Hemel Hempstead,
UK).
Serum PON1 activity towards paraoxon, PON1 concentration
and PON1 genotypes (Q192R, L55M, C-108T) were deter-
mined by our previously published methods [13].
 
Isolation of HDL
 
HDL (
 
d 
 
1.063–1.21 g/l) was isolated by sequential ultracen-
trifugation as described [24].
 
Preparation and oxidation of erythrocyte membranes
 
Human erythrocyte ghosts were prepared as described [10].
Briefly, heparinized blood samples of healthy subjects were
collected after an overnight fast and centrifuged at 1468 
 
g
 
, 4
 
°
 
C
for 20 min to separate the cells. Cells were then washed with
0.9% sodium chloride (NaCl) solution and incubated in 5 m
 
M
 
ice-cold phosphate-buffered saline (PBS) for 10 min to lyse the
cells. The cells were centrifuged at 5000 
 
g
 
 for 20 min to isolate the
membranes, which were washed in saline until all haemoglobin
was removed. Membrane protein concentration was determined
by the bicinchoninic acid (BCA) method.
Erythrocyte membranes (5 mg) were oxidized by incubation
with 5  m
 
M
 
 2,2-azo-bis(2-aminidinopropane) dihydrochloride
(AAPH) for 20 h at 37
 
°
 
C. Oxidation was terminated by re-
frigeration and the membranes separated by centrifugation
at 5000 
 
g
 
 for 20 min. The oxidized membranes were re-
suspended in saline. Oxidized erythrocyte membranes (500 
 
μ
 
g)
were incubated in the presence or absence of 100 
 
μ
 
g HDL total
protein, isolated from the study populations or glycated or
glyoxidized HDL for 3 h at 37
 
°
 
C, after which time membranes
were separated by centrifugation at 5000 
 
g
 
 for 20 min and the
membranes re-suspended in saline. Lipid hydroperoxides in the
membranes and HDL were determined using the xylenol orange
method [10].
 
Glycation/glyoxidation of HDL
 
To prepare glycated HDL, HDL (1 mg) isolated from a pool of
healthy control subjects was incubated in a final volume of
1 ml of N
 
2
 
-saturated PBS containing 40 mM BHT (butylated
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hydoxytoluene) and 25  m
 
M
 
 glucose for 1  week at 37
 
°
 
C.
Glyoxidation was achieved by incubating HDL with the omission
of BHT and N
 
2
 
. Control incubations omitted glucose.
 
Measurement of glycated PON1
 
The concentration of glycated PON1 in serum and HDL was
determined by boronate affinity chromatography [25]. Briefly,
serum or HDL were diluted 1 : 20 with PBS containing 1%
triton X100 to dissociate the HDL complex and subject to m-
aminophenylboronate affinity chromatography. Glycated and
non-glycated PON1 were then determined by our in-house
ELISA [13]. Briefly, standards, glycated and non-glycated PON1
samples were diluted 1 : 4500 in 0.05 
 
M
 
 carbonate buffer pH 9.6,
100 
 
μ
 
l added to duplicate wells of a 96-well plate and incubated
for 16 h at room temperature (22
 
°
 
C). Wells were washed with
PBS pH 7.4 containing 0.1% bovine serum albumin (PBS/
BSA) and incubated with PBS/1% BSA for 1 h at room temper-
ature. Following washing (
 
×
 
 3) rabbit anti-human PON1 IgG
diluted 1 : 6400 in PBS/1% BSA was added and incubated
for 1 h at room temperature. Wells were washed (
 
×
 
 2), anti-rabbit
peroxidase conjugate (1 : 2500) added and incubated for 1 h at
room temperature. Wells were then washed (
 
×
 
 3) and tetrame-
thylbenzidine substrate added. After 15 min at room temper-
ature, 2 
 
M
 
 sulphuric acid was added and the absorbance read at
450 nm. Recovery of PON1 in the two fractions was 96 
 
±
 
 1.8%
by reference to the original serum value.
 
Statistical analysis
 
Statistical analysis was performed using SPSS 10.0 (SPSS Inc.,
Chicago, IL, USA). All parameters were tested for normality
using the one-Sample Kolmogorov–Smirnov test. Statistically
significant differences between variables with a Gaussian distri-
bution were sought by Student’s unpaired 
 
t
 
-test. Variables with
a non-Gaussian distribution were compared using the Mann–
Whitney 
 
U
 
-test. One-way 
 
ANOVA
 
 was used to show any effect of the
PON1 polymorphisms on the variables investigated. Correlations
between parameters were examined using Pearsons’ coefficient.
The expected frequency of PON1 alleles were analysed by
the Hardy–Weinberg equilibrium test. The 
 
χ
 
2
 
-test was used to
determine the significance of differences in allele frequency. All
statistical analyses were conducted using SPSS version 10.0.
 
Results
 
The demographic and clinical details of the study groups have
been published previously [22] (Table 1). Compared with the
control subjects, both the groups with Type 2 diabetes and
CHD had higher serum triglycerides and significantly lower
PON1 activity and concentration. The group with Type 2
diabetes had higher body mass index (BMI), while the group
with CHD had lower HDL cholesterol and apoA1. Serum total
cholesterol was not significantly different between the groups,
probably because all the patients were receiving statin therapy.
There were no differences in the distribution of the PON1-L55M,
Q192R or C-108T polymorphisms between the groups [22].
HDL from the three study populations was able to metabolize
cell membrane lipid hydroperoxides (Fig. 1); however, HDL
from people with Type 2 diabetes and CHD were significantly
less able to metabolize membrane hydroperoxides than
HDL from control subjects (both 
 
P
 
 
 
<
 
 0.05), by 20–25%. The
concentration of lipid peroxides in the HDL fractions did not
differ between the groups (result not shown) nor was it higher
than in control incubations with unoxidized membranes,
indicating metabolism of the membrane hydroperoxides
rather than simple transfer to HDL. In the control group, there
was a significant negative correlation (
 
r
 
 
 
=
 
 
 
−
 
0.911, 
 
P
 
 
 
<
 
 0.001)
between the ability of HDL to metabolize membrane hydro-
peroxides and PON1 activity (Fig. 2), indicating a primary
role for PON1 in the metabolism of these hydroperoxides.
Although there were correlations between PON1 activity and
Table 1 Characteristics of the study groups
Parameters Control Type 2 diabetes CHD
n (male)  19 (10)  36 (21)  37 (22)
Age (years) 57.7 ± 4.8 57.7 ± 5.2 57.7 ± 5.4
BMI (kg/m2) 21.2 ± 3.2 28.8 ± 5.0** 25.3 ± 4.0
HbA1c (%) — 7.6 ± 1.4 —
Total cholesterol (mmol/l) 4.8 ± 1.6 5.1 ± 1.5 4.4 ± 1.0
Triglycerides (mmol/l)† 1.05 (0.51–3.27) 2.24** (0.68–9.27) 1.73** (0.64–3.21)
HDL cholesterol (mmol/l) 1.55 ± 0.41 1.29 ± 0.59 1.05 ± 0.34**
ApoB (mg/dl) 78.0 ± 59.5 88.0 ± 31.2 82.3 ± 21.0
ApoA1 (mg/dl) 110.5 ± 38.3 128.7 ± 46.3 85.1 ± 20.0**
PON1 activity† (nmol/min/ml) 269.4 (68.2–487.2) 113.6** (40.2–409.4) 150.9** (40.2–463.8)
PON1 mass† (μg/ml) 113.1 (35.2–239) 90.1* (17.6–175.9) 83.5* (19.4–124.9)
Significantly different from control *P < 0.05, **P < 0.01.
Values are mean ± SD except † which are median (range).
Apo, apolipoprotein; BMI, body mass index; CHD, coronary heart disease; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; 
PON1, paraoxonase-1; SD, standard deviation.
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HDL hydroperoxide metabolism, these did not reach statisti-
cal significance in the Type 2 diabetes (
 
r
 
 
 
=
 
 
 
−
 
0.624, 
 
P
 
 
 
=
 
 0.058)
or CHD (
 
r
 
 
 
=
 
 
 
−
 
0.598, 
 
P
 
 
 
=
 
 0.06) groups.
In all three study groups, HDL containing the PON1-
192RR isoform was significantly (
 
P
 
 
 
<
 
 0.01) less able to metab-
olize membrane hydroperoxides than HDL containing the
PON1-192Q isoform (Fig.  3). There was no effect of the
PON1-55 or PON1-108 polymorphisms.
The amount of glycated PON1 in serum increased from
7.5% in control subjects to 12% in those with CHD and 17%
in those with Type 2 diabetes (both 
 
P
 
 
 
<
 
 0.01) (Fig. 4). The
PON1-192 genotype, but not the PON1-55 or PON1-108
genotypes, affected the amount of glycation of PON1 (Fig. 5).
In all three study populations, the RR isoform was signifi-
cantly less glycated (
 
P
 
 
 
<
 
 0.01) than either the QR and QQ
isoforms, indicating possible structural differences between
the PON1 isoforms.
We next investigated whether the glycation and glyoxida-
tion of PON1 on HDL was a reason for the perturbed ability
of HDL to metabolize membrane hydroperoxides. PON1
activity towards paraoxon was reduced by 60% in glycated
HDL and by over 80% in glyoxidized HDL (
 
P
 
 
 
<
 
 0.001) com-
pared with normal HDL (Fig. 6). Similarly, compared with
normal HDL, the ability of glycated HDL to metabolize mem-
brane hydroperoxides was reduced by 50% (
 
P
 
 
 
<
 
 0.001) and
that of glyoxidized HDL by 80% (
 
P
 
 
 
<
 
 0.001) (Fig. 7).
FIGURE 1 Metabolism of membrane lipid 
hydroperoxides by HDL from the three study 
populations. Oxidized erythrocyte membranes 
(500 μg) were incubated in the presence or 
absence of 100 μg HDL for 3 h at 37°C. 
Membranes were isolated and hydroperoxides 
measured as described in Patients and methods. 
Data are mean ±  SD. Significantly different from 
HDL from control subjects. *P < 0.05. 
CHD, coronary heart disease; HDL, high-
density lipoprotein; ox, oxidized; SD, standard 
deviation.
FIGURE 2 Effect of paraoxonase-1 (PON1) activity on the ability 
of high-density lipoprotein (HDL) to metabolize membrane 
hydroperoxides. Experimental details can be found in Patients and 
methods.
FIGURE 3 Effect of the PON1-192 genotype on the ability of HDL to 
metabolize membrane hydroperoxides. PON1 genotypes were 
determined by PCR/RFLP analysis. Membrane hydroperoxides were 
determined as described in Fig. 1. Data are mean ± SD. Significantly 
different from the PON1-192 QQ and QR genotypes *P < 0.01. 
CHD, coronary heart disease; HDL, high-density lipoprotein; 
PON1, paraoxonase-1; SD, standard deviation; T2D, Type 2 diabetes.
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Discussion
We have shown for the first time that a significant fraction of
PON1 is glycated in vivo and that approximately twice as
much PON1 from people with Type 2 diabetes and those with
CHD is glycated compared with control subjects. Although
none of our CHD population had elevated glucose at the time
of study, we cannot exclude previous transient hyperglycaemic
episodes, for example, postprandially, as a reason for the
increased glycation of PON1, nor can we exclude the possibility
of increased PON1 half-life in this population. Interestingly, in
a previous study, apoB was found to be glycated in the order
of control  < CHD <  Type  2 diabetes, with no difference in
fasting glucose between control subjects and those with CHD
[25]. We have also shown that HDL from people with Type 2
diabetes and those with CHD is significantly less able to
metabolize erythrocyte membrane lipid hydroperoxides than
control HDL and there is a significant linear relationship
between lipid hydroperoxide metabolism and HDL-PON1
activity in control subjects but not in people with Type 2
diabetes or those with CHD, indicating a derangement in the
FIGURE 4 Percentage of glycated paraoxonase-1 (PON1) in sera from 
control, Type 2 diabetic patients and patients with coronary heart 
disease (CHD). Serum glycated and non-glycated PON1 were separated 
by boronate affinity chromatography and their concentrations measured 
by ELISA as described in Patients and methods. Data are mean ± SD 
(standard deviation). Significantly different from control subjects 
*P < 0.01.
FIGURE 5 Percentage of glycation of PON1 isoforms according to 
PON1-192 genotype. See Figs 3 and 4 for experimental details. Data are 
mean ± SD. Significantly different from the PON1-192 QQ and QR 
genotypes *P < 0.001. CHD, coronary heart disease; PON1, 
paraoxonase-1; SD, standard deviation; T2D, Type 2 diabetes.
FIGURE 6 Effect of glycation/glyoxidation on paraoxonase-1 (PON1) 
activity towards paraoxon. PON1 activity was determined using 
paraoxon as substrate in 100 μg control high-density lipoprotein (HDL) 
or HDL glycated or glyoxidized as described in the Patients and methods. 
Activity data for control HDL is presented after 7 days’ incubation. 
Compared with HDL before incubation the activity loss is 10 ± 0.9%. 
Data are mean ± SD (standard deviation). Significantly different from 
control HDL *P < 0.005, **P < 0.001.
FIGURE 7 Effect of glycation/glyoxidation on paraoxonase-1 (PON1) 
activity towards membrane hydroperoxides. One-hundred-microgram 
quantities of control, glycated or glyoxidized high-density lipoprotein 
(HDL) were incubated with oxidized erythrocyte membranes and 
hydroperoxides determined as described in Fig. 1. Data are mean ± SD 
(standard deviation). Significantly different from control HDL 
*P < 0.01, **P < 0.001.
dme(08)_2546.fm  Page 1053  Tuesday, August 26, 2008  10:33 AMDIABETICMedicine PON1 and membrane hydroperoxide metabolism • M. Mastorikou et al.
© 2008 The Authors.
1054 Journal compilation © 2008 Diabetes UK. Diabetic Medicine, 25, 1049–1055
ability of HDL to metabolize lipid peroxides in these people as
we have found previously [22]. Very similar results were
reported previously for HDL from people with Type 1 diabetes
[10].
It has previously been reported that in vitro glycation
inhibits PON1 activity towards paraoxon [21]. In this study
we found that glycation of PON1 inhibited both paraoxon
hydrolysis and membrane lipid hydroperoxide metabolism by
approximately 50%; however, glyoxidation caused 80%
inhibition of these two PON1 activities. It is therefore possible
that the increased in vivo glycation of PON1 leads to its
glyoxidation and is responsible for the derangement of
membrane hydroperoxide metabolism found in HDL from
people with Type 2 diabetes and those with CHD. Modification
of HDL by glycation or oxidation affects its anti-atherosclerotic
properties such as reverse-cholesterol transport [20]. Having
deranged antioxidant activity towards membrane hydroper-
oxides would lead to increased oxidation of cells in the artery
wall, increased inflammation in the vessel wall and increased
atherosclerosis [26]. Although inhibition of PON1 by glycation
appears to be the most likely cause of our results, we cannot
discount the possibility that glycation of other HDL proteins
such as apoA1 or lecithin : cholesterol acyltransferase effects
PON1 activity and/or the ability of HDL to metabolize
hydroperoxides. This could be by disrupting HDL structure,
or glycation of apoA1 could effect its ability to modulate
PON1 function.
There were significant differences in both activity towards
membrane hydroperoxides and glycation of PON1 in the
PON1-192 but not the PON1-55 or PON1-108 genotypes.
The PON1-192R isoform was least efficient at metabolizing
membrane hydroperoxides, but also the least glycated. At first
this may seem to contradict the results presented earlier.
However, there are major structural differences between the
Q and R isoforms of PON1 [27]. The amino acid at PON1
position 192 is involved in HDL binding. The PON1-192Q
isoform binds to HDL with threefold lower affinity than the R
isoform and as a consequence has reduced stability, activity
and ability to promote macrophage cholesterol efflux [27]. It
is possible that the additional stability of the R isoform allows
it to resist inhibition by glycation, whereas the relatively
unstable Q isoform cannot.
Rosenblat et al. [28] have shown that some serum PON1 is
present in the lipoprotein deficient fraction (LPDS) and that
this enzyme is less able to reduce LDL oxidation or promote
macrophage cholesterol efflux than HDL-associated PON1.
These authors also found that there was significantly more
PON1 present in LPDS from subjects with Type 2 diabetes
than healthy control subjects and that this may be one reason
for the accelerated atherosclerosis associated with Type 2
diabetes. However, this is unlikely to affect the results pre-
sented here, as we used only isolated HDL, and it is more likely
that a direct inhibition of PON1 by glycation/glyoxidation
occurred. These results may also help to explain why PON1 is
an independent risk factor for coronary events [29].
The PON1-Q192R polymorphism determines a substrate-
dependent polymorphism [30]. Whereas some, such as parao-
xon, are hydrolysed more efficiently by the R isoform, others
are hydrolysed more efficiently by the Q isoform [31]. We and
others have shown that the R isoform is least efficient at
metabolizing a number of oxidized lipids, such as oxidized
PAPC [22,32,33]. In our current study, the R isoform was least
able to metabolize membrane hydroperoxides, consistent with
previous findings.
In conclusion, in people with Type 2 diabetes and those with
CHD, PON1 is heavily glycated in vivo. This appears to inhibit
its ability to metabolize membrane lipid hydroperoxides.
Although the differences between the populations are small,
they are significant and could contribute to greater inflam-
mation in the vessel wall and increased atherosclerosis in
these populations.
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